S&P 500   3,325.05 (+0.25%)
DOW   29,343.50 (+0.16%)
QQQ   222.71 (+0.19%)
AAPL   316.35 (+0.35%)
FB   221.32 (-0.20%)
MSFT   166.12 (-0.03%)
AMZN   1,867.33 (-0.56%)
CGC   24.52 (+0.91%)
NVDA   248.12 (-0.33%)
MU   57.32 (-0.62%)
GE   11.79 (-0.42%)
TSLA   507.87 (-1.09%)
AMD   50.70 (+1.87%)
ACB   2.09 (-2.79%)
PRI   128.46 (+0.07%)
BAC   34.68 (-0.12%)
GILD   62.93 (-0.43%)
DIS   145.09 (-0.02%)
S&P 500   3,325.05 (+0.25%)
DOW   29,343.50 (+0.16%)
QQQ   222.71 (+0.19%)
AAPL   316.35 (+0.35%)
FB   221.32 (-0.20%)
MSFT   166.12 (-0.03%)
AMZN   1,867.33 (-0.56%)
CGC   24.52 (+0.91%)
NVDA   248.12 (-0.33%)
MU   57.32 (-0.62%)
GE   11.79 (-0.42%)
TSLA   507.87 (-1.09%)
AMD   50.70 (+1.87%)
ACB   2.09 (-2.79%)
PRI   128.46 (+0.07%)
BAC   34.68 (-0.12%)
GILD   62.93 (-0.43%)
DIS   145.09 (-0.02%)
S&P 500   3,325.05 (+0.25%)
DOW   29,343.50 (+0.16%)
QQQ   222.71 (+0.19%)
AAPL   316.35 (+0.35%)
FB   221.32 (-0.20%)
MSFT   166.12 (-0.03%)
AMZN   1,867.33 (-0.56%)
CGC   24.52 (+0.91%)
NVDA   248.12 (-0.33%)
MU   57.32 (-0.62%)
GE   11.79 (-0.42%)
TSLA   507.87 (-1.09%)
AMD   50.70 (+1.87%)
ACB   2.09 (-2.79%)
PRI   128.46 (+0.07%)
BAC   34.68 (-0.12%)
GILD   62.93 (-0.43%)
DIS   145.09 (-0.02%)
S&P 500   3,325.05 (+0.25%)
DOW   29,343.50 (+0.16%)
QQQ   222.71 (+0.19%)
AAPL   316.35 (+0.35%)
FB   221.32 (-0.20%)
MSFT   166.12 (-0.03%)
AMZN   1,867.33 (-0.56%)
CGC   24.52 (+0.91%)
NVDA   248.12 (-0.33%)
MU   57.32 (-0.62%)
GE   11.79 (-0.42%)
TSLA   507.87 (-1.09%)
AMD   50.70 (+1.87%)
ACB   2.09 (-2.79%)
PRI   128.46 (+0.07%)
BAC   34.68 (-0.12%)
GILD   62.93 (-0.43%)
DIS   145.09 (-0.02%)
Log in

NYSE:IQV - Iqvia Stock Price, Forecast & News

$160.70
-0.27 (-0.17 %)
(As of 01/17/2020 12:35 PM ET)
Today's Range
$159.39
Now: $160.70
$161.69
50-Day Range
$143.41
MA: $151.80
$160.97
52-Week Range
$122.55
Now: $160.70
$164.13
Volume246,368 shs
Average Volume1.19 million shs
Market Capitalization$31.18 billion
P/E Ratio31.39
Dividend YieldN/A
Beta0.88
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorBusiness Services
CUSIPN/A
Phone919-998-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.41 billion
Cash Flow$11.21 per share
Book Value$34.76 per share

Profitability

Net Income$259 million

Miscellaneous

Employees58,000
Market Cap$31.18 billion
Next Earnings Date2/13/2020 (Estimated)
OptionableOptionable

Receive IQV News and Ratings via Email

Sign-up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.


T-Minus 16 hours until our next trade POPS... (Ad)


A Jump Trader caught a 58% gain in just ONE DAY...

Another, $2,080 in profit in just ONE DAY...

Every day you miss out on this could be costing you... $500...

$1,000... Even $2,080 a day...

Iqvia (NYSE:IQV) Frequently Asked Questions

What is Iqvia's stock symbol?

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

How were Iqvia's earnings last quarter?

Iqvia Holdings Inc (NYSE:IQV) issued its earnings results on Wednesday, October, 30th. The medical research company reported $1.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.57 by $0.03. The medical research company earned $2.77 billion during the quarter, compared to analysts' expectations of $2.76 billion. Iqvia had a return on equity of 16.95% and a net margin of 2.24%. The business's revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.42 EPS. View Iqvia's Earnings History.

When is Iqvia's next earnings date?

Iqvia is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Iqvia.

What guidance has Iqvia issued on next quarter's earnings?

Iqvia issued an update on its fourth quarter earnings guidance on Wednesday, October, 30th. The company provided earnings per share (EPS) guidance of $1.65-1.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.75. The company issued revenue guidance of $2.807-2.857 billion, compared to the consensus revenue estimate of $2.89 billion.

What price target have analysts set for IQV?

18 brokers have issued 1-year price targets for Iqvia's stock. Their forecasts range from $136.38 to $185.00. On average, they anticipate Iqvia's share price to reach $167.83 in the next year. This suggests a possible upside of 4.4% from the stock's current price. View Analyst Price Targets for Iqvia.

What is the consensus analysts' recommendation for Iqvia?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 2 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iqvia.

Has Iqvia been receiving favorable news coverage?

Media stories about IQV stock have trended positive on Friday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Iqvia earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Iqvia.

Are investors shorting Iqvia?

Iqvia saw a decline in short interest in the month of December. As of December 13th, there was short interest totalling 3,280,000 shares, a decline of 7.6% from the November 28th total of 3,550,000 shares. Based on an average trading volume of 1,360,000 shares, the short-interest ratio is presently 2.4 days. Currently, 1.9% of the shares of the company are sold short. View Iqvia's Current Options Chain.

Who are some of Iqvia's key competitors?

What other stocks do shareholders of Iqvia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Micron Technology (MU), Allergan (AGN), Alibaba Group (BABA), Athabasca Oil (ATH), Paypal (PYPL) and Accenture (ACN).

Who are Iqvia's key executives?

Iqvia's management team includes the folowing people:
  • Mr. Ari Bousbib, Chairman, Pres & CEO (Age 58)
  • Mr. Michael R. McDonnell, Exec. VP & CFO (Age 55)
  • Mr. Eric M. Sherbet, Exec. VP, Gen. Counsel & Sec. (Age 55)
  • Mr. W. Richard Staub III, Pres of R&D Solutions (Age 56)
  • Mr. Kevin C. Knightly, Pres of Information & Technology Solutions (Age 58)

Who are Iqvia's major shareholders?

Iqvia's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Arvest Bank Trust Division (0.11%), Artemis Investment Management LLP (0.07%), Howard Capital Management (0.06%), DNB Asset Management AS (0.06%), McGuire Investment Group LLC (0.05%) and State of Alaska Department of Revenue (0.04%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Group Holdings (Sbs) Advis Tpg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View Institutional Ownership Trends for Iqvia.

Which major investors are selling Iqvia stock?

IQV stock was sold by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, First Hawaiian Bank, State of Alaska Department of Revenue, Howard Capital Management, Arvest Bank Trust Division, Legacy Capital Partners Inc., Winslow Evans & Crocker Inc. and HWG Holdings LP. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Ronald A Rittenmeyer and W Richard Staub. View Insider Buying and Selling for Iqvia.

Which major investors are buying Iqvia stock?

IQV stock was bought by a variety of institutional investors in the last quarter, including McGuire Investment Group LLC, DNB Asset Management AS, Three Peaks Capital Management LLC, IFM Investors Pty Ltd, FTB Advisors Inc., Appleton Partners Inc. MA, Raymond James Trust N.A. and IFP Advisors Inc. View Insider Buying and Selling for Iqvia.

How do I buy shares of Iqvia?

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Iqvia's stock price today?

One share of IQV stock can currently be purchased for approximately $160.70.

How big of a company is Iqvia?

Iqvia has a market capitalization of $31.18 billion and generates $10.41 billion in revenue each year. The medical research company earns $259 million in net income (profit) each year or $5.12 on an earnings per share basis. Iqvia employs 58,000 workers across the globe.View Additional Information About Iqvia.

What is Iqvia's official website?

The official website for Iqvia is http://www.iqvia.com/.

How can I contact Iqvia?

Iqvia's mailing address is 4820 EMPEROR BLVD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]


MarketBeat Community Rating for Iqvia (NYSE IQV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  477 (Vote Outperform)
Underperform Votes:  424 (Vote Underperform)
Total Votes:  901
MarketBeat's community ratings are surveys of what our community members think about Iqvia and other stocks. Vote "Outperform" if you believe IQV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IQV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Featured Article: Closed-End Mutual Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel